Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Ashley Anderson |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder / Herriot Tabuteau en The American Journal of Psychiatry, Año 2022 - Vol. 179 - No.7 (Julio)
[artículo]
Título : Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder : a randomized double-blind controlled trial Tipo de documento: texto impreso Autores: Herriot Tabuteau, Autor ; Amanda Jones, Autor ; Ashley Anderson, Autor Fecha de publicación: 2022 Artículo en la página: pp. 490-499 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Dextrometorfano, Bupropión Resumen: Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. Link: ./index.php?lvl=notice_display&id=28583
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No.7 (Julio) . - pp. 490-499[artículo] Effect of axs-05 (dextromethorphan-bupropion) in major depressive disorder : a randomized double-blind controlled trial [texto impreso] / Herriot Tabuteau, Autor ; Amanda Jones, Autor ; Ashley Anderson, Autor . - 2022 . - pp. 490-499.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No.7 (Julio) . - pp. 490-499
Palabras clave: Trastorno depresivo mayor, Dextrometorfano, Bupropión Resumen: Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. Link: ./index.php?lvl=notice_display&id=28583